Colon

Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
Monday, November 6, 2023

SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the third quarter 2023 along with recent pipeline and corporate updates.

Key Points: 
  • SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the third quarter 2023 along with recent pipeline and corporate updates.
  • We look forward to continuing our work to improve the lives of people with cancer through Mirati discovered and developed therapeutics."
  • Excluding the August 2023 financing, net decrease in cash, cash equivalents and short-term investments for the third quarter of 2023 was $135.5 million.
  • Net KRAZATI product revenue for the three and nine months ended September 30, 2023 was $16.4 million and $36.1 million, respectively.

Global Capsule Endoscopy Market Projected to Reach $1,020.5 Million by 2030, Propelled by a Strong 9.6% CAGR - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 26, 2023

The global capsule endoscopy market is on a trajectory of significant growth, with expectations of reaching a substantial USD 1,020.5 million by 2030.

Key Points: 
  • The global capsule endoscopy market is on a trajectory of significant growth, with expectations of reaching a substantial USD 1,020.5 million by 2030.
  • The need for accurate and timely diagnosis of these conditions is driving the demand for capsule endoscopy.
  • In 2022, wireless capsule endoscopy dominated the market, driven by increased utilization rates for screening the esophagus, colon, and small intestine.
  • The global capsule endoscopy market presents significant growth opportunities driven by the need for advanced diagnostic tools and the rising prevalence of gastrointestinal disorders.

United Health Foundation Awards $2.3 Million Grant to Mary Bird Perkins Cancer Center to Increase Cancer Services in Underserved Communities

Retrieved on: 
Thursday, October 26, 2023

The United Health Foundation today announced a three-year, $2.3 million grant partnership with Mary Bird Perkins Cancer Center to help increase access to prostate and colorectal cancer education, screening and support for historically underserved individuals across Louisiana.

Key Points: 
  • The United Health Foundation today announced a three-year, $2.3 million grant partnership with Mary Bird Perkins Cancer Center to help increase access to prostate and colorectal cancer education, screening and support for historically underserved individuals across Louisiana.
  • Mary Bird Perkins Cancer Center works with community partners to offer screening events in various settings, including barbershops.
  • This support will enable Mary Bird Perkins Cancer Center to expand access to education and life-saving early detection cancer screenings for prostate and colorectal cancers in communities where it is needed most,” said Renea Duffin, vice president of cancer support and outreach, Mary Bird Perkins Cancer Center.
  • Please visit the Mary Bird Perkins Cancer Center website for a complete list of screening events and to learn more.

A century of research shows eating these compounds can help protect against heart disease and Alzheimer's

Retrieved on: 
Thursday, October 26, 2023

Perhaps the word “polyphenol” means little to you, but they certainly mean a lot to your health. Polyphenols are a family of chemical compounds present in foods of vegetable origin and seaweed that have been studied over the last century for their health effects.The beginning: taste and technologyUses date back to Ancient Egypt, when chemicals in the bark of certain trees were found to bind with the collagen in animal skin, making leather.

Key Points: 


Perhaps the word “polyphenol” means little to you, but they certainly mean a lot to your health. Polyphenols are a family of chemical compounds present in foods of vegetable origin and seaweed that have been studied over the last century for their health effects.

The beginning: taste and technology

  • Uses date back to Ancient Egypt, when chemicals in the bark of certain trees were found to bind with the collagen in animal skin, making leather.
  • This sensation, known as astringency, comes from the interaction between tannins and salivary proteins in your mouth.

Natural antioxidants

  • Polyphenols are natural antioxidants, which means they can counteract harmful free radicals in the body.
  • When animals eat a plant, the polyphenols’ antioxidant properties then in turn counteract free radicals in the animal’s body.
  • This antioxidant effect from foods is important for human health, since many diseases (cardiovascular diseases, cancer, type 2 diabetes, etc.)

Much more than antioxidants

  • This happened when several studies found that, once consumed, polyphenols are transformed by our bodies, mostly by our gut microbiota.
  • But the good news was that, besides their antioxidant activity, polyphenols were also discovered to have many more properties.
  • This has not only been observed in test tubes, but also in multiple clinical trials in different populations.

The gut-brain axis

  • Although much more research is still needed, some promising evidence shows that polyphenols may also help our cognitive function and improve our sleep.
  • There is, however, something known as the gut-brain axis.
  • This new field of research is very much in its infancy, with much left to be explored.

The future for polyphenol research

  • We have come a long way in our knowledge of dietary polyphenols over the last century.
  • Hopefully, we will have answers to some of these questions in years to come.
  • Jara Pérez Jiménez ha recibido, como investigadora principal, fondos en los últimos cinco años del Ministerio de Ciencia e Innovación (España) y la Comisión para la Uva de la Mesa de California.
  • Margaret Slavin has received, as principal investigator, funding over the past five years from the United States Department of Agriculture, George Mason University, and the American Egg Board/Egg Nutrition Center.

Motus GI Receives FDA Clearance to Commercialize Pure-Vu EVS Gastro and Gen 4 Colon

Retrieved on: 
Tuesday, October 24, 2023

FORT LAUDERDALE, Fla., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today that it has received clearance from the U.S. Food and Drug Administration (“FDA”) for the special 510(k) for technological advancements featured in the new Pure-Vu EVS Gastro and Gen 4 Colon system. The Pure-Vu EVS Gastro opens the critically important upper gastrointestinal (GI) portion of the market and access to the high acuity patients that suffer from an upper GI bleed where visualization to address this high mortality condition can be a significant issue. Both the Pure Vu EVS Gastro and the improved version for the colon each provide significant benefits compared to previous Pure-Vu models and are designed to potentially open new opportunities in the GI market by introducing new capabilities while also addressing factors that make it easier to work with commercial partners. Both products leverage the same workstation to create an effective platform to improve visualization in both the upper and lower GI tract to facilitate use in multiple indications, that can provide clinical benefit to patients and efficiencies for hospital systems.

Key Points: 
  • The Pure-Vu EVS Gastro opens the critically important upper gastrointestinal (GI) portion of the market and access to the high acuity patients that suffer from an upper GI bleed where visualization to address this high mortality condition can be a significant issue.
  • “We look forward to initiating market introduction of the Pure-Vu EVS Gastro and Gen 4 Colon in the U.S. by the end of the year.
  • Upper GI bleeds occurred in the U.S. at a rate of approximately 400,000 cases per year in 2019, according to iData Research Inc.
  • The mortality rate of this condition can reach up to approximately 10%, as noted in Thad Wilkins, MD, et al., American Family Physician (2012).

Biora Therapeutics to Submit Updated IND Application for BT-600

Retrieved on: 
Monday, October 23, 2023

SAN DIEGO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced an update regarding its Investigational New Drug (IND) application. The IND application supports the next phase of development of BT-600, a drug/device combination designed to use Biora’s NaviCap™ ingestible drug delivery device with a proprietary liquid formulation of tofacitinib, for the treatment of moderate to severe ulcerative colitis.

Key Points: 
  • (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced an update regarding its Investigational New Drug (IND) application.
  • We plan to address the agency’s questions and submit our updated filing, potentially as early as this week,” said Ariella Kelman, MD, Chief Medical Officer of Biora Therapeutics.
  • The IND application for BT-600 includes extensive manufacturing, preclinical, human device function, and toxicology data to support a first-in-human clinical trial for BT-600.
  • The NaviCap device has been designed for targeted delivery directly to the colon in this application.

Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise

Retrieved on: 
Monday, October 23, 2023

VANCOUVER, BC, Oct. 23, 2023 /PRNewswire/ -- USA News Group - Despite being a relatively rare form of cancer, pancreatic cancer remains one of the deadliest in the oncology field, the third leading cause of cancer death in the USA. Still not fully understood, pancreatic cancer's 5-year survival rate is currently only 12%. New analysis of data from the National Program of Cancer Registries database, covering around 65% of the US population, suggests that the incidence of pancreatic cancer among individuals younger than 55 years is increasing more rapidly than in those 55 years or older, and also more quickly in women than in men. As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder. Thankfully, within the biotech sector, there have been plenty of developments giving hope in the fight against pancreatic cancer, including those from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Eli Lilly and Company, Roche Holding AG (OTC:RHHBY), BioNTech SE (NASDAQ:BNTX), and even 23andMe Holding Co (NASDAQ:ME).

Key Points: 
  • As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder .
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • The BRCA1 and BRCA2 variants may also be associated with an increased risk for prostate cancer, pancreatic cancer, and potentially other cancers.
  • "It's an important milestone that shows we're headed in the right direction – and this means so much to all those affected by pancreatic cancer."

Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise

Retrieved on: 
Monday, October 23, 2023

VANCOUVER, BC, Oct. 23, 2023 /PRNewswire/ -- USA News Group - Despite being a relatively rare form of cancer, pancreatic cancer remains one of the deadliest in the oncology field, the third leading cause of cancer death in the USA. Still not fully understood, pancreatic cancer's 5-year survival rate is currently only 12%. New analysis of data from the National Program of Cancer Registries database, covering around 65% of the US population, suggests that the incidence of pancreatic cancer among individuals younger than 55 years is increasing more rapidly than in those 55 years or older, and also more quickly in women than in men. As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder. Thankfully, within the biotech sector, there have been plenty of developments giving hope in the fight against pancreatic cancer, including those from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Eli Lilly and Company, Roche Holding AG (OTC:RHHBY), BioNTech SE (NASDAQ:BNTX), and even 23andMe Holding Co (NASDAQ:ME).

Key Points: 
  • As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder .
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • The BRCA1 and BRCA2 variants may also be associated with an increased risk for prostate cancer, pancreatic cancer, and potentially other cancers.
  • "It's an important milestone that shows we're headed in the right direction – and this means so much to all those affected by pancreatic cancer."

Olympus Announces Market Launch of EVIS X1™ Endoscopy System

Retrieved on: 
Thursday, October 19, 2023

CENTER VALLEY, Pa., Oct. 19, 2023 /PRNewswire/ -- Olympus Corporation, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced today the market launch of its next-generation EVIS X1™ endoscopy system, which will be on display and demonstrated Oct. 22-24 during the American College of Gastroenterology (ACG) annual meeting in Vancouver, Canada.

Key Points: 
  • The EVIS X1 endoscopy system received clearance earlier this year along with two compatible endoscopes: the GIF-1100 gastrointestinal videoscope indicated for use within the upper digestive tract and the CF-HQ1100DL/I colonovideoscope indicated for use within the lower digestive tract.
  • These are adjunctive tools for endoscopic examination that can be used to supplement Olympus white light imaging.
  • The addition of new imaging technologies in the EVIS X1 endoscopy system may help physicians to visualize these abnormalities.
  • Olympus' portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments.

Hoag Welcomes Dr. Ronald Wolf as Medical Director of Hepatobiliary and Pancreatic Surgery

Retrieved on: 
Tuesday, October 17, 2023

NEWPORT BEACH, Calif. and IRVINE, Calif., Oct. 17, 2023 /PRNewswire/ -- Hoag is proud to announce the recruitment of Ronald Wolf, M.D., F.A.C.S., as medical director of hepatobiliary and pancreas surgery at Hoag Family Cancer Institute.

Key Points: 
  • NEWPORT BEACH, Calif. and IRVINE, Calif., Oct. 17, 2023 /PRNewswire/ -- Hoag is proud to announce the recruitment of Ronald Wolf, M.D., F.A.C.S., as medical director of hepatobiliary and pancreas surgery at Hoag Family Cancer Institute.
  • Dr. Wolf comes to Hoag from concurrent posts at UC Irvine School of Medicine, where he served as professor of clinical surgery in the hepatobiliary and pancreas surgery/islet cell transplantation division.
  • Prior to that, he served as Medical Director of Hepatic and Pancreatic Surgery at Legacy Good Samaritan Medical Center in Portland, Oregon, and as the Medical Director of Liver and Pancreas Surgery at Providence Cancer Center, also in Portland.
  • Dr. Wolf received his medical degree from Oregon Health & Science University in Portland, followed by an internship and two residencies in general surgery at UC Davis.